Holen Sie sich die Stockscreener-App
3.83
29.60%
-1.61
Handel nachbörslich:
3.96
0.13
+3.39%
Schlusskurs vom Vortag:
$5.44
Offen:
$5.11
24-Stunden-Volumen:
2.01M
Relative Volume:
1.51
Marktkapitalisierung:
$3.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-5.85M
KGV:
-0.5727
EPS:
-6.6877
Netto-Cashflow:
$-8.00M
1W Leistung:
+4.93%
1M Leistung:
-35.97%
6M Leistung:
-67.26%
1J Leistung:
-92.68%
1-Tages-Spanne:
$3.7001
$5.20
1-Wochen-Bereich:
$3.25
$8.22
52-Wochen-Spanne:
$3.0558
$135.54
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
3500 LENOX RD. NE, ATLANTA
Vergleichen Sie ALZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
3.83 | 2.68M | 0 | -5.85M | -8.00M | -6.6877 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Promising Pharmaceutical Stocks To Follow Today – May 29th - Defense World
Alzamend Neuro (NASDAQ:ALZN) Stock Rating Upgraded by Wall Street Zen - Defense World
Lithium Stocks To Consider – May 29th - Defense World
Alzamend Neuro doses first patient in Phase II study of AL001 - TipRanks
Alzamend Neuro (ALZN) Begins Phase II Clinical Study of AL001 | - GuruFocus
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled By Stocktwits - Investing.com India
Lithium Stocks To ConsiderMay 29th - MarketBeat
Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone - Benzinga
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - MSN
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results - Benzinga
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue - Benzinga
Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update - TipRanks
Alzamend Neuro Soars on Breakthrough Trial News: Is This Biotech Stock a Hidden Gem? - RagingBull
Alzamend Neuro Announces Dosing Of First Patient In Phase II Clinical Trial Of Al001 "Lithium In Brain" Study - marketscreener.com
Alzamend Neuro begins phase II trial for novel lithium delivery system - Investing.com
Alzamend Neuro Announces Dosing of First Patient in its - GlobeNewswire
Novel Lithium Drug Enters Phase II Trial, Targets 43M Patients With Brain Disorders Without Blood Monitoring - Stock Titan
Alzamend begins phase II trial for novel lithium therapy By Investing.com - Investing.com South Africa
Alzamend begins phase II trial for novel lithium therapy - Investing.com Australia
Alzamend Neuro (ALZN) Commences Phase II Trial for Innovative Al - GuruFocus
Alzamend Neuro (ALZN) Commences Phase II Trial for Innovative Alzheimer's Treatment | ALZN Stock News - GuruFocus
Alzamend Neuro Enrolls First Patient in its Phase II - GlobeNewswire
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study - marketscreener.com
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
Alzamend Neuro (ALZN) Begins Key Phase II Trials of AL001 | ALZN Stock News - GuruFocus
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 'Lithium in Brain” Study Taking Place at Massachusetts General Hospital - The Manila Times
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants - Benzinga
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
Alzamend Neuro to conduct reverse stock split - MSN
Alzamend Neuro adds partners for lithium study using specialty head coil - AuntMinnie
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com India
Alzamend Neuro Announces Reverse Stock Split Plan - TipRanks
Stock Market Recap: Alzamend Neuro Inc (ALZN) Concludes at 0.60, a -6.22 Surge/Decline - DWinneX
Alzamend Neuro (ALZN) Announces Reverse Stock Split | ALZN Stock News - GuruFocus
Alzamend Neuro Announces Reverse Stock Split - The Manila Times
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements - Investing.com
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital - BioSpace
Alzamend Neuro partners with Mint Labs to support five upcoming trials - TipRanks
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered - GlobeNewswire
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical ... - Eagle-Tribune
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program - Yahoo
Geode Capital Management LLC Buys New Stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) - Defense World
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Seeking Alpha
ALZNAlzamend Neuro Inc Latest Stock News & Market Updates - Stock Titan
Alzamend Neuro, Inc.Common Stock (Nasdaq:ALZN) Stock Quote - FinancialContent
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 37.6% in April - Defense World
Form 8-KCurrent report - ADVFN
ALZN Stock Sees Decline of Approximately -12.99% in Last Five Days - knoxdaily.com
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):